Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03415178 · ClinicalTrials.gov registry record · Phase 3
Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
A Phase 3 study of Hypercholesterolaemia, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 69
- Enrollment target
- 13
- Study locations
NCT03415178: Completed Phase 3 study of Hypercholesterolaemia, sponsored by Sanofi.
NCT03415178 is a Phase 3 study of Hypercholesterolaemia that has completed, run by Sanofi. The registered enrollment target is 69 participants, below the 5,033-participant average among 3 other Hypercholesterolaemia trials with a reported enrollment target (99% lower). The trial reports 13 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03415178, a Phase 3 study of Hypercholesterolaemia, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 69 participants
- Enrollment target
- 13
- Study locations
Study Summary
Primary Objective: To collect real-use (usability) data assessing the robustness and user interaction of the new alirocumab auto-injector device (which is referred to as SYDNEY), in unsupervised settings. Secondary Objective: Device-related: * To collect real-use (usability) data assessing the robustness and user interaction of SYDNEY and the current alirocumab auto-injector device (which is referred to as AI) in supervised settings. Pharmacokinetics: * To compare alirocumab pharmacokinetics (PK) administered using SYDNEY and AI. * To evaluate alirocumab PK administered using SYDNEY. Anti-drug antibodies: * To evaluate the development of anti-drug (alirocumab) antibodies (ADA). Efficacy/pharmacodynamics: * To compare the percent and absolute change in low-density lipoprotein cholesterol (LDL-C) using SYDNEY and AI. * To evaluate the percent and absolute change in LDL-C using SYDNEY. Safety: * To evaluate the safety and tolerability of alirocumab using both SYDNEY and AI.
Primary Outcome
SYDNEY-associated PTC was defined as any complaint reported on the participant complaint form that triggered an investigation by the device department and was categorized as either device-related, participant-related, or undetermined whether or not associated with an adverse event (AE). Overall category included total of all 3 types of PTCs. The percentage of SYDNEY-associated PTCs was calculated as: Number of PTCs / Number of unsupervised injections\*100. The confidence interval (CI) was calcul
Conditions Studied
Interventions
- DRUG Rosuvastatin
- DRUG Atorvastatin
- DRUG Alirocumab SAR236553
- DEVICE Current auto-injector device (AI)
- DEVICE New auto-injector device (SYDNEY)
Study Locations (13)
Florida
- Investigational Site Number 8400007 - Jacksonville
- Investigational Site Number 8400017 - Jacksonville
- Investigational Site Number 8400013 - Ponte Vedra
- Investigational Site Number 8400014 - Wellington
Ohio
- Investigational Site Number 8400006 - Cincinnati
- Investigational Site Number 8400010 - Cincinnati
California
- Investigational Site Number 8400024 - Los Angeles
Iowa
- Investigational Site Number 8400001 - West Des Moines
Kansas
- Investigational Site Number 8400019 - Topeka
South Carolina
- Investigational Site Number 8400022 - Summerville
Texas
- Investigational Site Number 8400026 - Amarillo
Virginia
- Investigational Site Number 8400005 - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2018-03-29 |
| Est. Completion | 2018-08-09 |
| Phase | Phase 3 |
What the finished NCT03415178 record still lists
NCT03415178 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 5,033-participant average among 3 other Hypercholesterolaemia trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Hypercholesterolaemia appearing as the primary indexed condition, and to 5 interventions - of which Rosuvastatin is the first listed.
NCT03415178 lists 13 locations in 9 states (Florida, Ohio, California).
Frequently Asked Questions
What is clinical trial NCT03415178 about?
NCT03415178 is a clinical study titled "Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy". Primary Objective: To collect real-use (usability) data assessing the robustness and user interaction of the new alirocumab auto-injector device (which is referred to as SYDNEY), in unsupervised settings. Secondary Objective: Device-related: * To collect real-use (usability) data assessing the r...
What is the current status of trial NCT03415178?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 69 participants. The study started on 2018-03-29. Estimated completion is 2018-08-09.
What conditions does trial NCT03415178 study?
This clinical trial studies the following conditions: Hypercholesterolaemia.
What interventions are being tested in trial NCT03415178?
The interventions under investigation include: Rosuvastatin (DRUG), Atorvastatin (DRUG), Alirocumab SAR236553 (DRUG), Current auto-injector device (AI) (DEVICE), New auto-injector device (SYDNEY) (DEVICE).
Who is sponsoring clinical trial NCT03415178?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03415178 being conducted?
This trial has 13 study locations across California, Florida, Iowa, Kansas, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolaemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
COMPLETED · Phase 3
-
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI